Left atrial appendage closure in atrial fibrillation: A world without anticoagulation?

17Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Atrial Fibrillation (AF) is a common arrhythmia with an incidence that is as high as 10 in the elderly population. Given the large proportion of strokes caused by AF as well as the associated morbidity and mortality, reducing stroke burden is the most important part of AF management. While warfarin significantly reduces the risk of AF-related stroke, perceived bleeding risks and compliance limit its widespread use in the high-risk AF population. The left atrial appendage is believed to be the culprit for thrombogenesis in nonvalvular AF and is a new therapeutic target for stroke prevention. The purpose of this review is to explore the evolving field of percutaneous LAA occlusion. After briefly highlighting the risk of stroke with AF, problems with warfarin, and the role of the LAA in clot formation, this article discusses the feasibility and efficacy of various devices which have been developed for percutaneous LAA occlusion. Copyright © 2011 Tahmeed Contractor and Atul Khasnis.

Cite

CITATION STYLE

APA

Contractor, T., & Khasnis, A. (2011). Left atrial appendage closure in atrial fibrillation: A world without anticoagulation? Cardiology Research and Practice. https://doi.org/10.4061/2011/752808

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free